CGON

79.4702.97%
JJ

James J. Mule

Independent Director

Dr. James J. Mule, Ph.D., M.D., also known as Jim, serves as Advisor at ORI Capital. Dr. Mule serves as a Member of Scientific Advisory Board at Vault Nano Inc. He is an Independent Director at CG Oncology, Inc. (formerly known as Cold Genesys, Inc.). since October 22, 2018. He has been Member of Scientific Advisory Board at Ankyra Therapeutics, Inc. since 2022. Dr. Mule serves as Member of Scientific Advisory Board at Turnstone Biologics Inc. since December 2021. He serves as Member of the Scientific Advisory Board at Turnstone Biologics Corp. He served as Member of Scientific Advisory Board at AffyImmune Therapeutics, Inc. since June 2021 until July 2025 and serves as its Member of Clinical and Regulatory Advisory Board since April 2024. Dr. Mule serves as Executive Vice President Applied Science at H. Lee Moffitt Cancer Center & Research Institute, Inc. Dr. Mule serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He is a Special Government Employee of the NCI and the FDA. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He served as a Director of the Tumor Immunology and Immunotherapy Clinical Research Program at the University of Michigan Comprehensive Cancer Center at Ann Arbor, Mich. He served as Head of Scientific Advisory Board at Aleta Biotherapeutics, Inc until December 2025. He was also the Maude T. Lane Endowed Professor of Surgery, Department of Surgery and held the appointment of Professor in the Department of Internal Medicine. He is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. He has been Member of Scientific Advisory Board at Oxis Biotech, Inc. since January 15, 2015. He serves as a Director of BioFlorida. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves on the Board of Directors of Medicine in Need, Cambridge, MA and is a member of the Scientific and Medical Advisory Board of Aura Biosciences; selected as 2011 and 2010 Technology Pioneers, respectively, by the World Economic Forum, Davos. He serves as a Member of Scientific Advisory Board at Iovance Biotherapeutics, Inc. He serves as a Member of Advisory Board at Stony Hill Corp. He serves as Member of Advisory Board at Vault Pharma. He serves as a Member of Scientific Advisory Board at OncoPep, Inc. Dr. Mule serves as a Member of Scientific Advisory Board of Lion Biotechnologies, Inc. He serves as Member of Advisory Board at UbiVac, LLC. Dr. Mule serves as a Member of Advisory Board at NCI-designated Cancer Centers and was a member of the NCI Director's Board of Scientific Counselors (BSC-A, clinical). Dr. Mule served as a Member of Scientific Advisory Board at OXIS International, Inc. He served as a Member of Scientific Advisory Board of Lycera Corp. He serves as on the Scientific/Medical Advisory Boards of numerous privately or publicly held companies including Celgene and Genesis. He served as Member of Scientific Advisory Board at GT Biopharma, Inc. He served as a Member of Scientific Advisory Board at Etubics Corporation until August 27, 2015. He served as a Member of Scientific & Medical Advisory Board at Antigen Express, Inc. since May 17, 2012. He served as Member of Scientific and medical advisory team at Antigen Express, Inc. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA. He was Member of Scientific Advisory Board at Applied Biosciences Corp. until 2020. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors. His clinical research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. Dr. Mule has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy. He was honored as the 25th Meadow Brook Lecturer in Medicine and Surgery. He received a special individual Ph.D. (IPh.D.) degree in Tumor Immunology from the Fred Hutchinson Cancer Research Center and the University of Washington. He subsequently received his post-graduate training at the Surgery Branch, Division of Cancer Treatment at the National Cancer Institute, where he became a Senior Investigator with tenure. He has M.S. in Cellular Immunology from the University of Washington School of Medicine and a B.A. from New Jersey City University.

Positions